These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 22156263)

  • 1. [Science of new drug development and regulatory review].
    Ono S
    Nihon Yakurigaku Zasshi; 2011 Dec; 138(6):252-5. PubMed ID: 22156263
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 3. [Regulatory science promoting improvement in developing environment of innovative drugs].
    Kawanishi T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2013; (131):2-6. PubMed ID: 24340663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two decades of new drug development for central nervous system disorders.
    Kesselheim AS; Hwang TJ; Franklin JM
    Nat Rev Drug Discov; 2015 Dec; 14(12):815-6. PubMed ID: 26585536
    [No Abstract]   [Full Text] [Related]  

  • 5. [New perspective for drug discovery and clinical development in kidney disease].
    Miyata T; Kikuchi K; Saito K
    Nihon Jinzo Gakkai Shi; 2012; 54(5):610-4. PubMed ID: 22991841
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug development in Japan from the viewpoints of global pharmaceutical companies].
    Seriu T
    Rinsho Ketsueki; 2009 Jul; 50(7):556-62. PubMed ID: 19638723
    [No Abstract]   [Full Text] [Related]  

  • 7. A need for speed: Signals in drug development.
    Nat Med; 2012 Dec; 18(12):1730-1. PubMed ID: 23223053
    [No Abstract]   [Full Text] [Related]  

  • 8. The 21st Century Cures Act: can the regulatory framework survive the "cures"?
    Osorio-de-Castro CG; Caetano R; Pepe VL
    Cad Saude Publica; 2015 Sep; 31(9):1807-10. PubMed ID: 26578005
    [No Abstract]   [Full Text] [Related]  

  • 9. The current state of drug discovery and what it might take to improve drug discovery outcomes and approval successes.
    Turner MJ
    Drug Discov Today; 2015 Aug; 20(8):917-9. PubMed ID: 26100736
    [No Abstract]   [Full Text] [Related]  

  • 10. Regulatory watch: Outcomes of EMA marketing authorization applications: does partnering have an influence?
    van den Bogert CA; Souverein PC; Putzeist M; Leufkens HG; Janssen SW; Koëter GH
    Nat Rev Drug Discov; 2014 Dec; 13(12):878. PubMed ID: 25394870
    [No Abstract]   [Full Text] [Related]  

  • 11. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 12. Accelerated vaccine development against emerging infectious diseases.
    Leblanc PR; Yuan J; Brauns T; Gelfand JA; Poznansky MC
    Hum Vaccin Immunother; 2012 Jul; 8(7):1010-2. PubMed ID: 22777091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The complexity of integrating speed and safety in drug development and approval.
    Charo RA
    JAMA Intern Med; 2013 Jul; 173(13):1165-6. PubMed ID: 23568604
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development and perspective for the Biosimilar medicines].
    Takayasu Y; Tsukamoto T
    Nihon Yakurigaku Zasshi; 2016 May; 147(5):303-9. PubMed ID: 27181727
    [No Abstract]   [Full Text] [Related]  

  • 15. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
    Asano K; Tanaka A; Sato T; Uyama Y
    Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current situations and the future prospect of monoclonal antibody products].
    Yamaguchi T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2014; (132):36-46. PubMed ID: 25707201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities.
    Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J
    Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Re-engineering drug discovery and development.
    FitzGerald GA
    LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Industry and regulatory performance in 2012: a year in review.
    Dowden HM; Jahn R; Catka T; Jonsson A; Michael E; Miwa Y; Zinkand W
    Clin Pharmacol Ther; 2013 Sep; 94(3):359-66. PubMed ID: 23657160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.